(Total Views: 525)
Posted On: 09/12/2022 7:16:16 PM
Post# of 148878
Spot on Figgs, I completely agree.
This is completely in line with the priority set in the 10-K.
1. Strengthening our pharmacovigilance program enabling us to remove the FDA clinical holds placed on our HIV
and COVID-19 programs to allow us to conduct future clinical studies.
2. Advancing our NASH program to a Phase 2b or Phase 2b/3 trial for steatosis and liver fibrosis associated with
NASH.
3. Exploring a study for patients with HIV and NASH.
4. Contining our Phase 2 program for metastatic triple-negative breast cancer with current standard of care, explore
a Phase 2 colon cancer trial with current standard of care, and explore other solid tumor indications.
5. Continuing our work to evaluate the feasibility and timelines for the HIV BLA resubmission and explore other
cancer and immunologic indications for leronlimab, continue our work on developing a long-acting version of
leronlimab, and pursue proof of concept studies for HIV cure using leronlimab and AAV vectors.
6. Reviewing our strategy for our COVID-19 program.
This is completely in line with the priority set in the 10-K.
1. Strengthening our pharmacovigilance program enabling us to remove the FDA clinical holds placed on our HIV
and COVID-19 programs to allow us to conduct future clinical studies.
2. Advancing our NASH program to a Phase 2b or Phase 2b/3 trial for steatosis and liver fibrosis associated with
NASH.
3. Exploring a study for patients with HIV and NASH.
4. Contining our Phase 2 program for metastatic triple-negative breast cancer with current standard of care, explore
a Phase 2 colon cancer trial with current standard of care, and explore other solid tumor indications.
5. Continuing our work to evaluate the feasibility and timelines for the HIV BLA resubmission and explore other
cancer and immunologic indications for leronlimab, continue our work on developing a long-acting version of
leronlimab, and pursue proof of concept studies for HIV cure using leronlimab and AAV vectors.
6. Reviewing our strategy for our COVID-19 program.
(4)
(0)Scroll down for more posts ▼
